Tetra can benefit from this development agreement using its current know-how: “This agreement reflects the many potential therapeutic benefits of our Adversa® delivery technology,” said Dr. Horst G. Zerbe, CEO of IntelGenx. Adversa is not only particularly suitable for patients who have difficulty swallowing capsules – a common and unfortunate side effect of chemotherapy® – but it also offers efficacy comparable to that of capsules with a potentially higher adverse reaction profile. “1.2. TETRA reserves the right to modify, modify, add or delete all or part of this contract at any time. Amendments to this Agreement shall be published in the www.tetratec.com. It is important that you refer to this Agreement from time to time to ensure that you are aware of any additions, revisions or changes we have made to this Agreement. .